[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577802":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":44,"centralContacts":45,"locations":51,"responsibleParty":71,"collaborators":75,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":44,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":44,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":54,"whyStopped":44,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Bir Hospital","OTHER_GOV",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Tamsulosin group","ACTIVE_COMPARATOR","placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily, to relieve the symptom",[13],"Drug: Tamsulosin Hydrochloride 0.4 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Solifenacin group","placement of ureteral stents followed by Tab Solifenacin 5 mg once daily, to relieve the symptom",[18],"Drug: Solifenacin Succinate 5 mg",{"label":20,"type":10,"description":21,"interventionNames":22},"Mirabegron group","placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily, to relieve the symptom",[23],"Drug: Mirabegron 25 mg",[25,32,38],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Tamsulosin Hydrochloride 0.4 mg","placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily",[9],[31],"Cap. Urimax 0.4 mg",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Solifenacin Succinate 5 mg","placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily",[15],[37],"Tab. Solay 5 mg",{"type":26,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Mirabegron 25 mg","placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily",[20],[43],"Tab. Mirasin 25 mg",null,[46],{"name":47,"role":48,"phone":49,"phoneExt":44,"email":50},"Baikuntha Adhikari, MCh","CONTACT","+977 9849896780","baikadhe@gmail.com",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"NAMS, Bir Hospital","RECRUITING","Kathmandu","Bagmati","44600","Nepal","NP",{"type":61,"coordinates":62},"Point",[63,64],85.3206,27.70169,{"lat":64,"lon":63},[67],{"name":68,"role":48,"phone":69,"phoneExt":44,"email":70},"Jainendra K Manoj, Dr","9841529629","drjkmanoj@gmail.com",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"PRINCIPAL_INVESTIGATOR","Jainendra Kumar Manoj","M Ch Urology Resident",[76],{"name":77,"class":6},"Nepal Health Research Council","100577802","phase-3-study-of-tamsulosin-solifenacin-and-mirabegron-in-alleviating-ureteral-stent-related-symptoms-100577802",false,"NCT06803030","Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms","A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial","Inclusion Criteria:\n\n• Eligible participants were adult patients (aged 19-80 years) who underwent unilateral retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteric stent insertion for urinary tract stones\n\nExclusion Criteria:\n\n* Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics\n* Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy\n* Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases\n* Preoperative febrile Urinary Tract Infection (UTI)\n* Pregnancy or breastfeeding;\n* A single kidney\n* Moderate or severe cardiovascular or cerebrovascular disease\n* Hepatic dysfunction\n* History of pelvic surgery or irradiation\n* History of bladder or prostate surgery\n* Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the Ureteral Stent Symptom Questionnaire(USSQ) pain score\n* Allergy to any medication","ALL","18 Years","80 Years",{"count":89,"type":90},189,"ESTIMATED","INTERVENTIONAL",[93],"PHASE3","A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.",[96],"Ureteral Stent-Related Symptom",[98,99,100],"Mirabegron","Tamsulosin","Solifenacin","2025-08-30",{"date":103,"type":104},"2025-09-08","ACTUAL",{"date":101,"type":104},{"date":107,"type":90},"2026-12-31",{"name":5,"class":6},1]